Literature DB >> 15772834

Cyclosporine A monitoring--how to account for twice and three times daily dosing.

Samuel Fanta1, Janne T Backman, Paula Seikku, Christer Holmberg, Kalle Hoppu.   

Abstract

Cyclosporine A (CsA) dose-interval pharmacokinetic profiles, performed 1-4 years post-transplantation, were collected from 74 renal transplanted children. Forty patients were on three times daily dosing (t.i.d.) and 34 on twice daily dosing (b.i.d.). Regression models for prediction of area under the curve (AUC) using 1-3 concentration time points as independent variables were developed. With similar weight-adjusted single doses (mg kg(-1)) of CsA, t.i.d. dosing resulted in a trough-concentration (C0) similar to that from b.i.d. dosing, but a 30% lower 2 h post-dose concentration (C2). For b.i.d. dosing the relationship between C0 and AUC was poor (r2=0.23) and the prediction error was large (5.8+/-33.5%). For t.i.d. dosing the relationship was better (r2=0.79), but prediction error was still large (4.5+/-24.9%). For C2 relationships were similar to those for the b.i.d. (r2=0.59) and t.i.d. (r2=0.63) groups, but explained modestly the variations of AUC (prediction error=2.6+/-16.8% b.i.d., 4.8+/-23.2% t.i.d.). Both C0 and C2 are useful monitoring methods when CsA is administered t.i.d. If the aim is similar specified daily drug exposure, the target C2 should be roughly 30% smaller in t.i.d. dosing than in b.i.d. dosing and the target C0 could be similar. The prediction error of AUC can be large in individual patients when using single time-point determinations, however. The use of multiple time points reduces the variation, but is less feasible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772834     DOI: 10.1007/s00467-004-1802-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  36 in total

Review 1.  Patient management by Neoral C(2) monitoring: an international consensus statement.

Authors:  Gary Levy; Eric Thervet; John Lake; Kazuharu Uchida
Journal:  Transplantation       Date:  2002-05-15       Impact factor: 4.939

2.  High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection.

Authors:  B D Kahan
Journal:  Transplant Proc       Date:  1998-08       Impact factor: 1.066

Review 3.  Cyclosporin pharmacokinetics in paediatric transplant recipients.

Authors:  G F Cooney; K Habucky; K Hoppu
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

4.  The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group.

Authors:  G Barone; C T Chang; M G Choc; J B Klein; C L Marsh; J A Meligeni; D I Min; M D Pescovitz; R Pollak; T L Pruett; J B Stinson; J S Thompson; E Vasquez; T Waid; D G Wombolt; R L Wong
Journal:  Transplantation       Date:  1996-03-27       Impact factor: 4.939

5.  Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; A E Lison; K Kutz
Journal:  Transplantation       Date:  1994-04-27       Impact factor: 4.939

6.  A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation.

Authors:  Elias David-Neto; Lilian Pereira Araujo; Cristiane Feres Alves; Nairo Sumita; Pascoalina Romano; Elisa Midori Yagyu; William Carlos Nahas; Luiz Estevam Ianhez
Journal:  Pediatr Transplant       Date:  2002-08

7.  Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.

Authors:  B D Kahan; J Dunn; C Fitts; D Van Buren; D Wombolt; R Pollak; R Carson; J W Alexander; M Choc; R Wong
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

8.  A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation.

Authors:  H U Meier-Kriesche; B Kaplan; P Brannan; B D Kahan; R J Portman
Journal:  Ther Drug Monit       Date:  1998-08       Impact factor: 3.681

9.  Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection.

Authors:  B D Kahan; M Welsh; L Schoenberg; L P Rutzky; S M Katz; D L Urbauer; C T Van Buren
Journal:  Transplantation       Date:  1996-09-15       Impact factor: 4.939

10.  Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible.

Authors:  T D Batiuk; F Pazderka; J Enns; L DeCastro; P F Halloran
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more
  2 in total

Review 1.  Renal transplantation in infants.

Authors:  Hannu Jalanko; Ilkka Mattila; Christer Holmberg
Journal:  Pediatr Nephrol       Date:  2015-06-27       Impact factor: 3.714

2.  Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.

Authors:  S Fanta; S Jönsson; J T Backman; M O Karlsson; K Hoppu
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.